share_log

Panbela Therapeutics | 424B3: Prospectus

Panbela Therapeutics | 424B3: Prospectus

Panbela Therapeutics | 424B3：募资说明书
美股SEC公告 ·  08/14 12:43
Moomoo AI 已提取核心信息
Panbela Therapeutics, Inc. filed a prospectus supplement on August 13, 2024, to update and supplement information in the Prospectus with the Quarterly Report filed on the same date. The supplement relates to the resale of 255,600 shares of common stock by selling securityholders. The company's common stock is quoted on the OTCQB under the symbol 'PBLA', with the last reported sales price being $0.35 per share as of August 12, 2024. The Quarterly Report details the company's financial status, including a net loss of $14.3 million for the six months ended June 30, 2024, and a decrease in cash from $2.578 million to $59,000. The report also mentions the ongoing ASPIRE trial for ivospemin (SBP-101) and the need for additional financing to continue operations. The company has incurred significant losses since inception and faces risks related to the need for additional capital, the success of development efforts, and obtaining regulatory approvals for product candidates.
Panbela Therapeutics, Inc. filed a prospectus supplement on August 13, 2024, to update and supplement information in the Prospectus with the Quarterly Report filed on the same date. The supplement relates to the resale of 255,600 shares of common stock by selling securityholders. The company's common stock is quoted on the OTCQB under the symbol 'PBLA', with the last reported sales price being $0.35 per share as of August 12, 2024. The Quarterly Report details the company's financial status, including a net loss of $14.3 million for the six months ended June 30, 2024, and a decrease in cash from $2.578 million to $59,000. The report also mentions the ongoing ASPIRE trial for ivospemin (SBP-101) and the need for additional financing to continue operations. The company has incurred significant losses since inception and faces risks related to the need for additional capital, the success of development efforts, and obtaining regulatory approvals for product candidates.
Panbela Therapeutics，Inc.于2024年8月13日提交招股书补充文件，以更新和补充同日提交的季度报告中的信息。该补充文件涉及由出售安全持有人转售255,600股普通股。该公司的普通股在OTCQb上以符号“PBLA”进行报价，截至2024年8月12日，最后报告的销售价格为每股$0.35。季度报告详细说明了公司的财务状况，包括截至2024年6月30日六个月的净亏损额为$14.3百万，现金从$2,578,000下降至$59,000。报告还提到了ivospemin（SBP-101）的正在进行的ASPIRE试验、需要额外融资以继续业务运营等方面的风险。该公司自成立以来一直在面临巨额亏损以及发展努力的成功和获取产品候选者的监管批准等方面的风险。
Panbela Therapeutics，Inc.于2024年8月13日提交招股书补充文件，以更新和补充同日提交的季度报告中的信息。该补充文件涉及由出售安全持有人转售255,600股普通股。该公司的普通股在OTCQb上以符号“PBLA”进行报价，截至2024年8月12日，最后报告的销售价格为每股$0.35。季度报告详细说明了公司的财务状况，包括截至2024年6月30日六个月的净亏损额为$14.3百万，现金从$2,578,000下降至$59,000。报告还提到了ivospemin（SBP-101）的正在进行的ASPIRE试验、需要额外融资以继续业务运营等方面的风险。该公司自成立以来一直在面临巨额亏损以及发展努力的成功和获取产品候选者的监管批准等方面的风险。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息